OncoMatch/Esophageal Cancer/HER2 (ERBB2)
Esophageal CancerHER2 (ERBB2) Clinical Trials
HER2 overexpression or amplification occurs in approximately 15–20% of esophageal and gastroesophageal junction (GEJ) adenocarcinomas; it is uncommon in esophageal squamous cell carcinoma. Trastuzumab added to platinum/fluoropyrimidine chemotherapy is first-line standard for HER2-positive GEJ/gastric adenocarcinoma; trastuzumab deruxtecan (T-DXd) is approved in the second-line setting. Trials investigate T-DXd first-line combinations and novel HER2-directed ADCs specifically for HER2-positive esophageal and GEJ adenocarcinoma.
Top recruiting HER2 (ERBB2) Esophageal Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
More HER2 (ERBB2) Esophageal Cancer trials
9 international trials (no US sites)
Browse other molecular targets with active Esophageal Cancer trials.